Relay Therapeutics reports third-quarter loss per share

Relay Therapeutics reported $848.6M in cash, equivalents and investments at September 30, 2026, versus $910.9M at June 30, 2026, and said funds are expected to cover expenses and capital needs into 2029. Q3 net loss was $81.7M, or $0.37 per share, versus $74.1M, or $0.43, a year earlier.Material De…